Literature DB >> 31949846

MicroRNA-142-3p inhibits proliferation and induces apoptosis by targeting the high-mobility group box 1 via the Wnt/β-catenin signaling pathway in glioma.

Chong Li1, Shiyu Feng1, Ling Chen1.   

Abstract

BACKGROUND: Glioma is one of the most common brain tumors. Copious microRNAs have been identified as critical regulators in the development of glioma. MicroRNA-142-3p (miR-142-3p) has been reported as a tumor suppressor in some malignancies. However, the roles and molecular mechanisms of miR-142-3p in the development of glioma are poorly defined.
METHODS: An RT-qPCR assay was carried out to detect expressions of miR-142-3p and high-mobility group box 1 (HMGB1) mRNA. A bioinformatic analysis and a luciferase reporter assay were used to explore the interaction between miR-142-3p and HMGB1 3'UTR. A Western blot assay was performed to examine protein expression of HMGB1, c-myc, cleaved caspase-3, and β-catenin. Cell proliferative ability was assessed by an MTS assay. The cell apoptotic rate was measured using flow cytometry via the double-staining of Annexin V-FITC and propidium iodide (PI).
RESULTS: MiR-142-3p expression was remarkably reduced in glioma tissues. Mechanical analyses showed that HMGB1 was a target of miR-142-3p. Functional investigations revealed that miR-142-3p suppressed proliferation and induced apoptosis by targeting HMGB1 in glioma cells. Moreover, miR-142-3p inactivated Wnt/β-catenin signaling and activated caspase-3 signaling by targeting HMGB1 in glioma cells.
CONCLUSION: MiR-142-3p inhibits proliferation and induces apoptosis by targeting HMGB1 via the Wnt/β-catenin signaling pathway in glioma cells, providing a deep exploration into the roles and molecular basis of miR-142-3p in the proliferation and apoptosis of glioma cells and highlighting the therapeutical values of miR-142-3p and HMGB1 for glioma. IJCEP
Copyright © 2018.

Entities:  

Keywords:  MicroRNA-142-3p; Wnt/β-catenin; glioma; high-mobility group box 1

Year:  2018        PMID: 31949846      PMCID: PMC6962963     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  39 in total

1.  Concordance of patient and caregiver reports in evaluating quality of life in patients with malignant gliomas and an assessment of caregiver burden.

Authors:  Daniel I Jacobs; Priya Kumthekar; Becky V Stell; Sean A Grimm; Alfred W Rademaker; Laurie Rice; James P Chandler; Kenji Muro; MaryAnne Marymont; Irene B Helenowski; Lynne I Wagner; Jeffrey J Raizer
Journal:  Neurooncol Pract       Date:  2014-05-05

2.  High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  R Stupp; M Brada; M J van den Bent; J-C Tonn; G Pentheroudakis
Journal:  Ann Oncol       Date:  2014-04-29       Impact factor: 32.976

3.  MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p.

Authors:  Ke Liu; Jun Huang; Jiangdong Ni; Deye Song; Muliang Ding; Junjie Wang; Xianzhe Huang; Wenzhao Li
Journal:  Cell Cycle       Date:  2017-02-10       Impact factor: 4.534

Review 4.  Advances in the molecular genetics of gliomas - implications for classification and therapy.

Authors:  Guido Reifenberger; Hans-Georg Wirsching; Christiane B Knobbe-Thomsen; Michael Weller
Journal:  Nat Rev Clin Oncol       Date:  2016-12-29       Impact factor: 66.675

Review 5.  MicroRNAs in Oncogenesis and Tumor Suppression.

Authors:  Simona Barbato; Giancarlo Solaini; Muller Fabbri
Journal:  Int Rev Cell Mol Biol       Date:  2017       Impact factor: 6.813

6.  Prognostic significance of the immunohistochemical staining of cleaved caspase-3, an activated form of caspase-3, in gliomas.

Authors:  Tatsuya Kobayashi; Junya Masumoto; Tsuyoshi Tada; Tetsuo Nomiyama; Kazuhiro Hongo; Jun Nakayama
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

7.  Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis.

Authors:  Zongbing You; Daniel Saims; Shaoqiong Chen; Zhaocheng Zhang; Denis C Guttridge; Kun-Liang Guan; Ormond A MacDougald; Anthony M C Brown; Gerard Evan; Jan Kitajewski; Cun-Yu Wang
Journal:  J Cell Biol       Date:  2002-04-29       Impact factor: 10.539

8.  PTEN-Foxo1 signaling triggers HMGB1-mediated innate immune responses in acute lung injury.

Authors:  Min Zhou; Yadi Zhang; Xulin Chen; Jianjun Zhu; Min Du; Liang Zhou; Ling Zhang; Wei Wang; Gengyun Sun
Journal:  Immunol Res       Date:  2015-05       Impact factor: 2.829

9.  HMGB1 mediates endogenous TLR2 activation and brain tumor regression.

Authors:  James F Curtin; Naiyou Liu; Marianela Candolfi; Weidong Xiong; Hikmat Assi; Kader Yagiz; Matthew R Edwards; Kathrin S Michelsen; Kurt M Kroeger; Chunyan Liu; A K M Ghulam Muhammad; Mary C Clark; Moshe Arditi; Begonya Comin-Anduix; Antoni Ribas; Pedro R Lowenstein; Maria G Castro
Journal:  PLoS Med       Date:  2009-01-13       Impact factor: 11.069

10.  High mobility group box 1-induced epithelial mesenchymal transition in human airway epithelial cells.

Authors:  Yu-Ching Chen; Sarah Statt; Reen Wu; Hao-Teng Chang; Jiunn-Wang Liao; Chien-Neng Wang; Woei-Cherng Shyu; Chen-Chen Lee
Journal:  Sci Rep       Date:  2016-01-07       Impact factor: 4.379

View more
  3 in total

1.  MicroRNA-142-3p Inhibits Tumorigenesis of Colorectal Cancer via Suppressing the Activation of Wnt Signaling by Directly Targeting to β-Catenin.

Authors:  Peng Liu; Fuao Cao; Jinke Sui; Yonggang Hong; Qizhi Liu; XianHua Gao; Haifeng Gong; Liqiang Hao; Zheng Lou; Wei Zhang
Journal:  Front Oncol       Date:  2021-02-10       Impact factor: 6.244

2.  The miR-142 Suppresses U-87 Glioblastoma Cell Growth by Targeting EGFR Oncogenic Signaling Pathway.

Authors:  Fatemeh Gheidari; Ehsan Arefian; Fatemeh Jamshidi Adegani; Fereshteh Fallah Atanaki; Masoud Soleimani
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

Review 3.  Recent insights into the microRNA-dependent modulation of gliomas from pathogenesis to diagnosis and treatment.

Authors:  Alireza Mafi; Atefe Rahmati; Zahra Babaei Aghdam; Raziyeh Salami; Marziyeh Salami; Omid Vakili; Esmat Aghadavod
Journal:  Cell Mol Biol Lett       Date:  2022-08-03       Impact factor: 8.702

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.